Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE: INO-4800 for COVID-19
NCT04642638Phase 3Terminated
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Nov 2020
- Primary completion
- Sep 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
A Phase 3 trial of INO-4800 in coronavirus disease 2019 (COVID-19), sponsored by Inovio Pharmaceuticals, Inc.. Started Nov 2020; status: terminated.
02
Drugs
INO-4800
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04642638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642638.